News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Press Releases
Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)
July 30, 2026
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)
Attachment
2026 Half-year Financial Report_Ipsen S.A.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
July 30, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
July 30, 2026
·
5 min read
·
Annalee Armstrong
Earnings
Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
July 29, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Incyte cuts early-stage cancer drug to focus on next-gen programs
July 29, 2026
·
2 min read
·
Tristan Manalac
